Research programme: oncolytic viruses - Virttu Biologics

Drug Profile

Research programme: oncolytic viruses - Virttu Biologics

Alternative Names: HSV-1716 variant; HSV-1716/NAT; HSV-1716Ing4; HSV-1790

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virttu Biologics
  • Class Gene therapies; Oncolytic viruses; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Sep 2016 Preclinical development is ongoing in United Kingdom (Virttu Biologics pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
  • 30 Apr 2008 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top